Drug Trial Radar · NCT04907370
PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma
Last checked: Nov 19, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
532
Actual
Start
Aug 1, 2021
Primary completion
Mar 1, 2025
Study completion Mar 1, 2027
Sponsor
- Lead sponsor
- Sun Yat-sen UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shanghai Junshi Bioscience Co., Ltd.
- First posted
- May 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the de-intensified chemoradiotherapy sparing concurrent cisplatin (i.e., toripalimab incorporated into induction chemotherapy and radiotherapy) in high-risk locoregionally advanced nasopharyngeal carcinoma.
Conditions
- Nasopharyngeal Carcinoma
Interventions
PD-1 blocking antibodyDrug
1. IC phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 3 cycles till the end of IC. 2. IMRT phase of PD-1 blocking antibody: every 3 weeks × 3 cycles; 240 mg, day 1; start on day 1 of IMRT or CCRT and continue every 3 weeks for 3 cycles till the end of IMRT. 3. Adjuvant PD-1 blocking antibody: every 3 weeks × 11 cycles; 240 mg, day 1
GemcitabineDrug
Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles
Cisplatin (80mg/m2)Drug
Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles
Cisplatin (100mg/m2)Drug
Cisplatin as concurrent chemotherapy, 100 mg/m2 day 1 per cycle, every 3 weeks for 2 cycles
Intensity-modulated radiotherapyRadiation
Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Failure-free survival (FFS)Time frame: 3-year
- Incidence rate of all-grade vomitingTime frame: Through study completion, an average of 1 year
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Chongqing Cancer Hospital
Chongqing, Chongqing Municipality, China
First People's Hospital of Foshan
Foshan, Guangdong, China
Panyu central hospital
Guangzhou, Guangdong, China
Cancer Hospital of Guangxi Medical University
Nanning, Guangxi, China
Cancer Hospital of Guizhou Medical University
Guiyang, Guizhou, China
Hubei Province Cancer Hosiptal
Wuhan, Hubei, China
Tongji Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China
Xiangya Hospital Central South University
Changsha, Hunan, China
Jiangxi Province Cancer Hospital
Nanchang, Jiangxi, China
Zhejiang Province Cancer Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.